Regulatory round-up: 2 September

Global regulators have been active over the past week, with a mix of policy updates, labeling changes, and priority review initiatives shaping the drug development landscape. From Washington to Tokyo, agencies are moving to tighten safety requirements while also speeding access to key therapies.

European and Asian regulators in particular have focused on clinical trial standards and post-marketing safety adjustments. Swissmedic and PMDA both issued notable technical guidance, signaling continued scrutiny of advanced therapies. Meanwhile, the TGA in Australia has updated manufacturing standards to align with international norms.

In Latin America and Africa, agencies are working to improve access and strengthen oversight. Anvisa launched a priority review initiative for leading diabetes medicines, while SAHPRA outlined a new framework for registration renewals. Together, these moves highlight the diverse but converging pressures on drug regulation worldwide.